Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

A new study published in The Journal of Dermatology showed that prurigo nodularis is associated with a considerably higher ...

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly what ...

A recently approved injectable eczema drug, Nemluvio, provides quick itch relief to patients with the maddening skin disease, ...

In a randomized clinical trial, vixarelimab demonstrates dose-dependent, long-term safety and efficacy in patients with ...

"Galderma’s Nemluvio shows itch reduction in 48 hours" was originally created and published by Clinical Trials Arena, a ...

Prurigo nodularis (PN) is a rare skin condition. It causes a rash and lumps to form on your skin, which may be severely itchy. Treatment involves relieving the itching. Share on Pinterest Prurigo ...

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

Vixarelimab led to rapid, dose-dependent reductions in itch severity compared with placebo, with more than 50% decreases in WI-NRS scores at week 16 in the high- and mid-dose groups, and meaningful ...

Please provide your email address to receive an email when new articles are posted on . These studies are the first published using Dupixent in this indication. The primary endpoint was met by up to ...

Prurigo nodularis (PN) is a long-lasting skin condition that causes very itchy, hard bumps, often all over the body. The itch can be so intense that people scratch until the skin breaks, leading to ...